Jennifer M Yeh1, Larissa Nekhlyudov, Sue J Goldie, Ann C Mertens, Lisa Diller. 1. Harvard School of Public Health, Harvard Medical School/Harvard Pilgrim Health Care Institute and Harvard Vanguard Medical Associates, Dana-Farber Cancer Institute and Children's Hospital, Boston, Massachusetts, and Emory University, Atlanta, Georgia, USA. jyeh@hsph.harvard
Abstract
BACKGROUND: Although childhood cancer survival rates have dramatically increased, survivors face elevated risk for life-threatening late effects, including secondary cancer. OBJECTIVE: To estimate the cumulative effect of disease- and treatment-related mortality risks on survivor life expectancy. DESIGN: State-transition model to simulate the lifetime clinical course of childhood cancer survivors. SETTING: Childhood Cancer Survivor Study. PATIENTS: Five-year survivors of childhood cancer. MEASUREMENTS: Probabilities of risk for death from the original cancer diagnosis, excess mortality from subsequent cancer and cardiac, pulmonary, external, and other complications, and background mortality (age-specific mortality rates for the general population) were estimated over the lifetime of survivors of childhood cancer. RESULTS: For a cohort of 5-year survivors aged 15 years who received a diagnosis of cancer at age 10 years, the average lifetime probability was 0.10 for late-recurrence mortality; 0.15 for treatment-related subsequent cancer and death from cardiac, pulmonary, and external causes; and 0.05 for death from other excess risks. Life expectancy for the cohort of persons aged 15 years was 50.6 years, a loss of 10.4 years (17.1%) compared with the general population. Reduction in life expectancy varied by diagnosis, ranging from 4.0 years (6.0%) for kidney tumor survivors to more than 17.8 years (> or =28.0%) for brain and bone tumor survivors, and was sensitive to late-recurrence mortality risk and duration of excess mortality risk. LIMITATION: Estimates are based on data for survivors who received treatment 20 to 40 years ago; patients who received treatment more recently may have more favorable outcomes. CONCLUSION: Childhood cancer survivors face considerable mortality during adulthood, with excess risks reducing life expectancy by as much as 28%. Monitoring the health of current survivors and carefully evaluating therapies with known late toxicities in patients with newly diagnosed cancer are needed.
BACKGROUND: Although childhood cancer survival rates have dramatically increased, survivors face elevated risk for life-threatening late effects, including secondary cancer. OBJECTIVE: To estimate the cumulative effect of disease- and treatment-related mortality risks on survivor life expectancy. DESIGN: State-transition model to simulate the lifetime clinical course of childhood cancer survivors. SETTING:Childhood Cancer Survivor Study. PATIENTS: Five-year survivors of childhood cancer. MEASUREMENTS: Probabilities of risk for death from the original cancer diagnosis, excess mortality from subsequent cancer and cardiac, pulmonary, external, and other complications, and background mortality (age-specific mortality rates for the general population) were estimated over the lifetime of survivors of childhood cancer. RESULTS: For a cohort of 5-year survivors aged 15 years who received a diagnosis of cancer at age 10 years, the average lifetime probability was 0.10 for late-recurrence mortality; 0.15 for treatment-related subsequent cancer and death from cardiac, pulmonary, and external causes; and 0.05 for death from other excess risks. Life expectancy for the cohort of persons aged 15 years was 50.6 years, a loss of 10.4 years (17.1%) compared with the general population. Reduction in life expectancy varied by diagnosis, ranging from 4.0 years (6.0%) for kidney tumor survivors to more than 17.8 years (> or =28.0%) for brain and bone tumor survivors, and was sensitive to late-recurrence mortality risk and duration of excess mortality risk. LIMITATION: Estimates are based on data for survivors who received treatment 20 to 40 years ago; patients who received treatment more recently may have more favorable outcomes. CONCLUSION:Childhood cancer survivors face considerable mortality during adulthood, with excess risks reducing life expectancy by as much as 28%. Monitoring the health of current survivors and carefully evaluating therapies with known late toxicities in patients with newly diagnosed cancer are needed.
Authors: T R Möller; S Garwicz; L Barlow; J F Winther; E Glattre; G Olafsdottir; J H Olsen; R Perfekt; A Ritvanen; R Sankila; H Tulinius Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 44.544
Authors: Amy C MacArthur; John J Spinelli; Paul C Rogers; Karen J Goddard; Zenaida U Abanto; Mary L McBride Journal: Pediatr Blood Cancer Date: 2007-04 Impact factor: 3.167
Authors: M C Cardous-Ubbink; R C Heinen; N E Langeveld; P J M Bakker; P A Voûte; H N Caron; F E van Leeuwen Journal: Pediatr Blood Cancer Date: 2004-06 Impact factor: 3.167
Authors: A C Mertens; Y Yasui; J P Neglia; J D Potter; M E Nesbit; K Ruccione; W A Smithson; L L Robison Journal: J Clin Oncol Date: 2001-07-01 Impact factor: 50.717
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Daniel A Mulrooney; Mark W Yeazel; Toana Kawashima; Ann C Mertens; Pauline Mitby; Marilyn Stovall; Sarah S Donaldson; Daniel M Green; Charles A Sklar; Leslie L Robison; Wendy M Leisenring Journal: BMJ Date: 2009-12-08
Authors: Josefine S Kornerup; Patrik Brodin; Charlotte Birk Christensen; Thomas Björk-Eriksson; Anne Kiil-Berthelsen; Lise Borgwardt; Per Munck Af Rosenschöld Journal: Pediatr Radiol Date: 2014-11-07
Authors: Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung Journal: Lancet Oncol Date: 2017-10-31 Impact factor: 41.316
Authors: Soad Fuentes-Alabi; Nickhill Bhakta; Roberto Franklin Vasquez; Sumit Gupta; Susan E Horton Journal: Cancer Date: 2017-09-15 Impact factor: 6.860
Authors: Randal K Wada; Darryl W Glaser; Erin O'Carroll Bantum; Trina Orimoto; Alana D Steffen; Jennifer L Elia; Cheryl L Albright Journal: Hawaii J Med Public Health Date: 2013-11
Authors: Leontien C M Kremer; Renée L Mulder; Kevin C Oeffinger; Smita Bhatia; Wendy Landier; Gill Levitt; Louis S Constine; W Hamish Wallace; Huib N Caron; Saro H Armenian; Roderick Skinner; Melissa M Hudson Journal: Pediatr Blood Cancer Date: 2012-12-31 Impact factor: 3.167